The parent grant CA10062 is focused on evaluation of function of myeloid-derived suppressor cells (MDSCs). During implementation of the research project we observed novel function of myeloid cells that are linked with the main focus of the grant but represent substantial extension of the proposed research. It is well established that the main causes of high mortality of lung cancer are frequent recurrence and metastasis. For patients with early stages non-small cell lung cancer (NSCLC) surgical resection is the treatment of choice. However, despite complete tumor resection followed by radiation control 30-60% of patients will undergo local or distant recurrence with limited benefit of adjuvant chemo- or targeted therapy. The reason for the recurrence remains unclear. It is widely accepted that small numbers of tumor cells persist in dormant state after early dissemination from primary tumor. Tumor microenvironment contribution to the development of lung cancer dormancy has been suggested. However, the mechanisms by which tumor cells are reawakened from dormancy remain poorly understood. This makes therapeutic targeting of this process is not possible. In this administrative supplement proposal, we will investigate the role of MDSC and activated neutrophils in re-activation of dormant tumor cells and evaluate a specific targeting strategy to block this effect.
Three specific aims are proposed.
Specific Aim 1. To identify the mechanism of PMN-mediated reactivation of dormant tumor cells in the models of genetic and chemotherapy-induced dormancy;
Specific Aim 2. To determine therapeutic effect of targeting S100A9/A8 and ?2-adrenergic receptors on re-activation of dormant tumor cells.
Specific Aim 3. To investigate the molecule mechanism underlying PMN-mediated escaping of senescence of dormant tumor cells This proposal is a collaborative effort of Dr. Gabrilovich, who has expertise in tumor immunology and cell biology and experience in studying neutrophils and MDSC, and Dr. Zhang who is molecular and cell biologist and an expert in studying of tumor cell senescence and dormancy.

Public Health Relevance

It is well established that the main causes of high mortality of lung cancer are frequent recurrence and metastasis. For patients with early stage non-small cell lung cancer (NSCLC) surgical resection is the treatment of choice. However, 30-60% of patients will have local or distant recurrence with limited benefit of adjuvant chemo- or targeted therapy. It is widely accepted that small numbers of tumor cells persist in a dormant state after early dissemination from primary tumor. In this administrative supplement proposal, we will investigate the role of MDSC and activated neutrophils in re-activation of dormant tumor cells and evaluate a specific targeting strategy to block this effect.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
3R01CA100062-14S1
Application #
9756540
Study Section
Program Officer
Howcroft, Thomas K
Project Start
2018-09-01
Project End
2019-08-31
Budget Start
2018-09-01
Budget End
2019-08-31
Support Year
14
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Tang, Chih-Hang Anthony; Chang, Shiun; Paton, Adrienne W et al. (2018) Phosphorylation of IRE1 at S729 regulates RIDD in B cells and antibody production after immunization. J Cell Biol 217:1739-1755
Zhou, Jie; Nefedova, Yulia; Lei, Aihua et al. (2018) Neutrophils and PMN-MDSC: Their biological role and interaction with stromal cells. Semin Immunol 35:19-28
Tcyganov, Evgenii; Mastio, Jerome; Chen, Eric et al. (2018) Plasticity of myeloid-derived suppressor cells in cancer. Curr Opin Immunol 51:76-82
Veglia, Filippo; Perego, Michela; Gabrilovich, Dmitry (2018) Myeloid-derived suppressor cells coming of age. Nat Immunol 19:108-119
Hashimoto, Ayumi; Gao, Chan; Mastio, Jerome et al. (2018) Inhibition of Casein Kinase 2 Disrupts Differentiation of Myeloid Cells in Cancer and Enhances the Efficacy of Immunotherapy in Mice. Cancer Res 78:5644-5655
Dominguez, George A; Condamine, Thomas; Mony, Sridevi et al. (2017) Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody. Clin Cancer Res 23:2942-2950
Gabrilovich, Dmitry I (2017) Myeloid-Derived Suppressor Cells. Cancer Immunol Res 5:3-8
Condamine, Thomas; Dominguez, George A; Youn, Je-In et al. (2016) Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Sci Immunol 1:
Kumar, Vinit; Cheng, Pingyan; Condamine, Thomas et al. (2016) CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation. Immunity 44:303-15
Bronte, Vincenzo; Brandau, Sven; Chen, Shu-Hsia et al. (2016) Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun 7:12150

Showing the most recent 10 out of 45 publications